Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

NCT05611853 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Stopped Due to company decision

Conditions

B-cell Lymphoma
Non Hodgkin Lymphoma
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma

Interventions

DRUG: BN301

Sponsor

BioNova Pharmaceuticals (Shanghai) LTD.